Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

Stopped Difficult enrollment due to changes in standard of care

Conditions

• Multiple Myeloma

Interventions

• DRUG: Daratumumab

Sponsor

Wake Forest University Health Sciences

Collaborators

• [object Object]